EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR T cell therapies in autoimmunity

Aaron Bodansky, David Jl Yu, Alysa Rallistan, Muge Kalaycioglu, Jim Boonyaratanakornkit, Damian J Green, Jordan Gauthier, Cameron J Turtle, Kelsey Zorn, Brian O'Donovan, Caleigh Mandel-Brehm, James Asaki und 22 weitere

Journal of Clinical Investigation · 01.07.2024 · 134 (13)

DOI: 10.1172/jci180012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 16.05.2024. Verfasst von Aaron Bodansky und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Critical Care, and. Hauptthemen laut MEDLINE: Proteome, Autoantibodies, Autoimmunity. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCATS NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Given the global surge in autoimmune diseases, it is critical to evaluate emerging therapeutic interventions. Despite numerous new targeted immunomodulatory therapies, comprehensive approaches to apply and evaluate the effects of these treatments longitudinally are lacking. Here, we leveraged advances in programmable-phage immunoprecipitation methodology to explore the modulation, or lack thereof, of autoantibody profiles, proteome-wide, in both health and disease. Using a custom set of over 730,000 human-derived peptides, we demonstrated that each individual, regardless of disease state, possesses a distinct and complex constellation of autoreactive antibodies. For each individual, the set of resulting autoreactivites constituted a unique immunological fingerprint, or “autoreactome,” that was remarkably stable over years. Using the autoreactome as a primary output, we evaluated the relative effectiveness of various immunomodulatory therapies in altering autoantibody repertoires. We found that therapies targeting B cell maturation antigen (BCMA) profoundly altered an individual’s autoreactome, while anti-CD19 and anti-CD20 therapies had minimal effects. These data both confirm that the autoreactome comprises autoantibodies secreted by plasma cells and strongly suggest that BCMA or other plasma cell–targeting therapies may be highly effective in treating currently refractory autoantibody-mediated diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteomeAutoantibodiesAutoimmunityHumansFemaleAutoimmune DiseasesMaleImmunotherapy, AdoptiveB-Cell Maturation AntigenAdultReceptors, Chimeric AntigenAntigens, CD19Middle Aged

Stichwörter der Autor:innen

Adaptive immunityAutoimmune diseasesAutoimmunityImmunotherapyTherapeutics

Substanzen

ProteomeAutoantibodiesB-Cell Maturation AntigenReceptors, Chimeric AntigenAntigens, CD19

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Critical Care, and.
  • Diabetes Center, School of Medicine, UCSF, San Francisco, California, USA.
  • Department of Medicine, Division of Immunology and Rheumatology, and.
  • Institute of Immunity, Transplantation, and Infection, Stanford University, Stanford, California, USA.
  • Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • University of Washington School of Medicine, Seattle, Washington, USA.

Förderung

  • NIGMS NIH HHS
  • NCATS NIH HHS
  • NIAID NIH HHS
  • NIAMS NIH HHS
  • NIA NIH HHS
  • NCI NIH HHS
  • NINDS NIH HHS
  • NICHD NIH HHS

Zitieren

APA

Bodansky, A., Yu, D. J., Rallistan, A., Kalaycioglu, M., Boonyaratanakornkit, J., Green, D. J., Gauthier, J., Turtle, C. J., Zorn, K., O'Donovan, B., Mandel-Brehm, C., Asaki, J., Kortbawi, H., Kung, A. F., Rackaityte, E., Wang, C. Y., Saxena, A., de Dios, K., Masi, G., …, & DeRisi, J. L. (2024). Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR T cell therapies in autoimmunity. Journal of Clinical Investigation, 134(13). https://doi.org/10.1172/jci180012

Vancouver

Bodansky A, Yu DJ, Rallistan A, Kalaycioglu M, Boonyaratanakornkit J, Green DJ, et al. Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR T cell therapies in autoimmunity. Journal of Clinical Investigation. 2024;134(13). doi:10.1172/jci180012

BibTeX
@article{Bodansky2024,
  author = {Bodansky, Aaron and Yu, David Jl and Rallistan, Alysa and Kalaycioglu, Muge and Boonyaratanakornkit, Jim and Green, Damian J and Gauthier, Jordan and Turtle, Cameron J and Zorn, Kelsey and O'Donovan, Brian and Mandel-Brehm, Caleigh and Asaki, James and Kortbawi, Hannah and Kung, Andrew F and Rackaityte, Elze and Wang, Chung-Yu and Saxena, Aditi and de Dios, Kimberly and Masi, Gianvito and Nowak, Richard J and O'Connor, Kevin C and Li, Hao and Diaz, Valentina E and Saloner, Rowan and Casaletto, Kaitlin B and Gontrum, Eva Q and Chan, Brandon and Kramer, Joel H and Wilson, Michael R and Utz, Paul J and Hill, Joshua A and Jackson, Shaun W and Anderson, Mark S and DeRisi, Joseph L},
  title = {Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR T cell therapies in autoimmunity},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  volume = {134},
  number = {13},
  doi = {10.1172/jci180012}
}
Kostenlos starten →